Slovak pharmaceutical manufacturer Imuna Pharm has reported a return to profitability after years of financial struggle. This positive result, alongside increased revenue, was largely driven by the sale of company assets. Despite the profit, Imuna’s financial situation remains precarious, and the company continues to face difficulties. Specifically, Imuna still owes approximately half a million euros in outstanding payments. The company, a well-known entity in eastern Slovakia, experienced a long period of losses and declining sales before this recent turnaround. While the asset sales provided a temporary boost, the long-term sustainability of Imuna’s recovery is still uncertain.